[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Langer F, Wintzer HO, Werner M, Weber C, Brümmendorf TH, Bokemeyer C: A case of pulmonary carcinosarcoma (squamous cell carcinoma and osteosarcoma) treated with cisplatin and doxorubicin. Anticancer Res; 2006 Sep-Oct;26(5B):3893-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of pulmonary carcinosarcoma (squamous cell carcinoma and osteosarcoma) treated with cisplatin and doxorubicin.
  • BACKGROUND: Pulmonary carcinosarcoma is a rare malignancy composed of epithelial and mesenchymal elements.
  • Little information is available on systemic treatment options for this tumor entity.
  • CASE REPORT: A 65-year-old man with severe chronic obstructive pulmonary disease (COPD) was diagnosed with primary pulmonary carcinosarcoma after percutaneous fine-needle biopsy of a right-sided calcified mass.
  • A second, non-calcified mass was present in the left lung.
  • The patient received six cycles of chemotherapy with cisplatin and doxorubicin, resulting in partial remission of both tumor manifestations.
  • CONCLUSION: Cisplatin and doxorubicin may be effective in pulmonary carcinosarcoma.
  • Nevertheless, the aggressiveness of this rare tumor entity, its histological heterogeneity, and its potential coexistence with non-small cell lung cancer (NSCLC) make the management of patients with pulmonary carcinosarcoma a diagnostic and therapeutic challenge.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Treatment Outcome


2. Goto T, Maeshima A, Oyamada Y, Kato R: Solitary pulmonary metastasis from prostate sarcomatoid cancer. World J Surg Oncol; 2010;8:101
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pulmonary metastasis from prostate cancer is considered to be a late event, and patients can be treated with chemotherapy or hormonal manipulation.
  • During postoperative follow-up, chest computed tomography showed a nodular shadow in the lung, and thoracoscopic wedge resection of the lung was performed.
  • CONCLUSION: Isolated pulmonary metastasis from prostate sarcomatoid cancer is extremely rare, but surgery could be the treatment of choice.
  • [MeSH-major] Carcinosarcoma / secondary. Lung Neoplasms / secondary. Pneumonectomy / methods. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Positron-Emission Tomography. Prostatectomy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Dec 15;54(12):3078-84 [6498785.001]
  • [Cites] Urol Clin North Am. 1991 Feb;18(1):55-63 [1899495.001]
  • [Cites] J Comput Assist Tomogr. 1999 Sep-Oct;23(5):761-3 [10524863.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2706-9 [7743474.001]
  • [Cites] J Urol. 1999 Dec;162(6):2102 [10569587.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Mil Med. 2000 Dec;165(12):973-4 [11149072.001]
  • (PMID = 21092117.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2995788
  •  go-up   go-down


3. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EUS revealed an 11 cm cystic mass in the head of the pancreas that was characterized as a carcinosarcoma/malignant mesodermal mixed tumor by EUS-FNA and Trucut needle biopsy.
  • The patient was treated with palliative chemotherapy and a three-month follow up CT scan did not reveal any new metastatic lesions.
  • CONCLUSION: The pancreas is a rare site of metastasis and more commonly seen in renal cell carcinoma, melanoma or lung tumors; amongst others.
  • [MeSH-minor] Aged. Biopsy, Fine-Needle / methods. Endosonography. Female. Humans. Neoplasm Staging. Pancreas / pathology. Pancreas / radiography. Prognosis. Tomography, X-Ray Computed


Advertisement
4. Nassar OA, Abdul Moaty SB, Khalil el-SA, El-Taher MM, El Najjar M: Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results. J Egypt Natl Canc Inst; 2010 Jun;22(2):113-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Uterine corpus sarcomas are rare heterogeneous tumors characterized by rapid progression and poor response to treatment.
  • This series investigated treatment options, relapse pattern, survival and prognostic factors.
  • Leiomyosarcoma accounted for 42.2% followed by carcinosarcoma (35.5%) and endometrial stromal sarcoma (18.6%).
  • Surgery was the primary line of treatment for all cases with total abdominal hysterectomy and bilateral salpingoophorectomy in 88% of cases and 12% had less extensive surgery.
  • Twenty-four (40.7%) patients had surgery alone, 24 (40.7%) had surgery and radiotherapy, 7 (11.9%) had surgery and chemo-irradiation and 4 (6.7%) had surgery and chemotherapy.
  • Neither extent of surgery, chemotherapy, histologic type or grade had significant effect on survival.
  • Adjuvant radiotherapy offered 62% 2-year cumulative overall survival versus 22% for surgery alone and surgery with chemotherapy.
  • Salvage surgery for isolated relapses was performed for 9/32 recurrent patients (28%) including 5 lung metastatectomies and 4 local pelvic resections.
  • CONCLUSION: Diagnosis of uterine sarcoma is in itself a poor prognostic factor.
  • KEY WORDS: Uterine cancer - Uterine sarcoma - Uterine sarcoma treatment - Sarcoma irradiation - Sarcoma prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21860468.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


5. Vidal Losada MJ, Bernal Monterde V, Amores Arriaga B, Ferrer Pérez AI, Serrano Solares S, Tobeña Puyal M: Lung carcinosarcoma. Clin Transl Oncol; 2010 Apr;12(4):303-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung carcinosarcoma.
  • Lung carcinosarcoma is a neoplasm of high grade composed of epithelial and mesenchymal cells.
  • Medical treatment, chemotherapy and radiotherapy are not active in this kind of tumour, so surgery is the treatment of choice.
  • We describe the diagnostic process and the clinical outcome of a patient with lung carcinosarcoma with several paraneoplastic syndromes.
  • [MeSH-major] Carcinosarcoma / diagnosis. Lung Neoplasms / diagnosis. Paraneoplastic Syndromes / physiopathology
  • [MeSH-minor] Aged. Bronchitis, Chronic / complications. Fatal Outcome. Heart Failure / complications. Humans. Male. Myocardial Ischemia / complications. Neoplasms, Second Primary / complications. Neoplasms, Second Primary / diagnosis. Pneumonectomy. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2007 Nov 17;370(9600):1736 [18022036.001]
  • [Cites] J Cardiovasc Surg (Torino). 1998 Feb;39(1):121-5 [9537548.001]
  • [Cites] Wiad Lek. 2007;60(3-4):189-91 [17726875.001]
  • [Cites] Chir Ital. 1994;46(3):27-8 [8001190.001]
  • [Cites] Age Ageing. 2007 Jul;36(4):468-9 [17412734.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Apr;23(4):461-6 [12694760.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2003 Dec;13(6):397-400 [14733704.001]
  • [Cites] Acta Pathol Jpn. 1992 Oct;42(10):751-4 [1466247.001]
  • [Cites] AJR Am J Roentgenol. 1997 Sep;169(3):691-4 [9275879.001]
  • [Cites] Mt Sinai J Med. 2003 Mar;70(2):130-2 [12634905.001]
  • [Cites] Eur J Cardiothorac Surg. 1996;10(6):403-7 [8817133.001]
  • (PMID = 20462841.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Wu HP, Feng GS, Tian Y: Hepatic artery infusion of antisense oligodeoxynucleotide and lipiodol mixture transfect liver cancer in rats. World J Gastroenterol; 2005 Apr 28;11(16):2408-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To study the distribution and stability of antisense oligodeoxynucleotide (ASODN) in Walker-256 cells and their distribution in liver, lung and kidney tissues after being infused alone or mixed with lipiodol via hepatic artery in a rat liver tumor model.
  • Its distribution in cells was observed by fluorescence microscope at different time points.
  • Walker-256 carcinosarcoma was transplanted into Wistar rat liver to establish a liver cancer model.
  • Frozen samples of liver, lung and kidney tissue were taken from rats after 1, 3 and 6 d, respectively.
  • In vivo experiment, on d 1 and 3 the fluorescence staining in liver was stronger in mixed group than in TAI group and more fluorescence could be detected in lung and kidney in TAI group than in mixed group.
  • In mixed group, ASODN was mainly distributed in liver tumor tissues.
  • ASODN mixed with lipiodol infusion via hepatic artery can be used in the treatment of HCC.
  • [MeSH-major] Carcinoma 256, Walker / drug therapy. Contrast Media / pharmacokinetics. Iodized Oil / pharmacokinetics. Liver Neoplasms / drug therapy. Oligodeoxyribonucleotides, Antisense / pharmacokinetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832409.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Fluorescent Dyes; 0 / Oligodeoxyribonucleotides, Antisense; 0 / Vascular Endothelial Growth Factor A; 8001-40-9 / Iodized Oil; I223NX31W9 / Fluorescein-5-isothiocyanate
  • [Other-IDs] NLM/ PMC4305626
  •  go-up   go-down


7. Sugie T, Takeuchi E, Kunishima F, Yotsumoto F, Kono Y: A case of ductal carcinoma with squamous differentiation in malignant phyllodes tumor. Breast Cancer; 2007;14(3):327-32
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinoma derived from the lining epithelial cells in malignant phyllodes tumor is a rare neoplasm of the breast and belongs to the category of carcinosarcoma.
  • A pathological diagnosis of ductal carcinoma with squamous differentiation was made by fine needle aspiration and a core needle biopsy.
  • She underwent neoadjuvant chemotherapy followed by a modified radical mastectomy with a skin flap.
  • She experienced lung and facial bone metastases, microscopic features of which were consistent with the sarcomatous component of the original breast carcinosarcoma.
  • This is an extremely rare case of carcinosarcoma and the histopathological findings and review of the literature are discussed.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Neoplasms, Multiple Primary / diagnosis. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690514.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Masue T, Taniguchi M, Takeuchi T, Sakai S: [A case report of sarcomatoid carcinoma of the bladder with metastasis to small intestine]. Nihon Hinyokika Gakkai Zasshi; 2005 Sep;96(6):640-3
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Under the clinical diagnosis of TCC G2 > G3, T3bNOM0, radical cystectomy with orthotopic bladder substitution was performed.
  • Pathological diagnosis was TCC G3 with sarcomatoid carcinoma, pT2pR0pL1 pVlpN0.
  • Adjuvant chemotherapy was not performed because of his transient poor conditions.
  • Lung metastasis was observed 6 months postoperatively.
  • Despite of M-VAC therapy and radiation therapy, additional metastases to brain and liver were observed.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinosarcoma / secondary. Ileal Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218407.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


9. Kitazawa R, Kitazawa S, Nishimura Y, Kondo T, Obayashi C: Lung carcinosarcoma with liposarcoma element: autopsy case. Pathol Int; 2006 Aug;56(8):449-52
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung carcinosarcoma with liposarcoma element: autopsy case.
  • Pulmonary carcinosarcoma, consisting of both carcinoma and sarcoma with a heterologous element, is a rare subtype, comprising approximately 0.3% of primary lung neoplasia.
  • The tumor did not respond to chemotherapy, and the patient died of respiratory failure and sepsis.
  • This is the first documented case of primary lung carcinosarcoma with a liposarcoma element.
  • [MeSH-major] Carcinosarcoma / pathology. Liposarcoma / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Daunorubicin / administration & dosage. Fatal Outcome. Humans. Male. Middle Aged. Radiography, Thoracic

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872439.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


10. Testa T, Nahum M, Ceppa P, Carbone E, Motta G: Carcinosarcoma of the lung: a case report. Tumori; 2000 Jan-Feb;86(1):82-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma of the lung: a case report.
  • The clinical and pathological data of a single case of carcinosarcoma of the lung observed in the period from 1978 to 1998 were reviewed.
  • The diagnosis was based on immunohistochemical examination of the surgical specimen after a lower left lobectomy.
  • The patient was given adjuvant chemotherapy.
  • [MeSH-major] Carcinosarcoma / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10778773.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Takami M, Idei T, Nakayama Y, Ohta H, Fukai H, Matsumoto H, Togo Y, Sakamoto H, Yamamoto T, Satoh K: [A case of advanced ovarian carcinosarcoma that responded remarkably to neoadjuvant chemotherapy of combined CPT-11 and CDDP]. Gan To Kagaku Ryoho; 2002 Feb;29(2):305-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced ovarian carcinosarcoma that responded remarkably to neoadjuvant chemotherapy of combined CPT-11 and CDDP].
  • Carcinosarcoma of the ovary is a very rare and highly malignant neoplasm that accounts for less than 1% of ovarian neoplasms.
  • Survival of patients with advanced stage cancer is poor and the best treatment is not clear.
  • We report the case of a 60-year-old woman who had Stage IV advanced heterogeneous ovarian carcinosarcoma with lung and liver metastases.
  • The lesions were considered surgically incurable, so she was placed on neoadjuvant chemotherapy of combination CPT-11 (60 mg/m2, day 1, 15) and CDDP (60 mg/m2, day 1).
  • Tumor markers of CA125 and LDH decreased remarkably to the normal level after 3 and 4 courses of chemotherapy, respectively.
  • After 7 courses of chemotherapy, the ovarian tumor was obviously reduced, and the lung and liver metastases had disappeared.
  • The current case suggests that combination CPT-11 and CDDP is effective against advanced ovarian carcinosarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinosarcoma / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Hysterotomy. Lymph Node Excision. Middle Aged. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11865639.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


12. Saint-Georges F, Terrier P, Sabourin JC, Bonvalot S, De Montpreville V, Ruffie P: [Pulmonary carcinosarcoma with jejunal metastasis: complete response to chemotherapy]. Rev Pneumol Clin; 2002 Sep;58(4 Pt 1):249-52
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary carcinosarcoma with jejunal metastasis: complete response to chemotherapy].
  • We report a case of pulmonary carcinosarcoma with jejunal metastasis.
  • The lung is an exceptional localization for carcinosarcoma, a tumor with carcinomatous and sarcomatous components.
  • Surgery is the treatment of choice for localized forms.
  • Prognosis depends on the sarcomatous component which is usually sensitive to chemotherapy, with at least doxorubicin and ifosfamide.
  • This rare case illustrates the potential for jejunal metastasis and complete response to chemotherapy, proven histologically at 33 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / drug therapy. Jejunal Neoplasms / drug therapy. Lung Neoplasms
  • [MeSH-minor] Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12407292.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


13. Pautier P, Genestie C, Fizazi K, Morice P, Mottet C, Haie-Meder C, Le Cesne A, Lhommé C: Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas. Int J Gynecol Cancer; 2002 Nov-Dec;12(6):749-54
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.
  • There is no standard therapy for cases of relapse, although chemotherapy is commonly used.
  • We studied the use of a cisplatin-based chemotherapy regimen for uterine sarcomas with an unusually long follow-up.
  • Group 1 consisted of patients undergoing adjuvant therapy (for initial disease, eight patients; for pelvic recurrence, two patients); Group 2 consisted of patients with advanced disease (locoregional after initial local therapy, five patients; local recurrence, six patients) or metastatic disease (stage IV, four patients; recurrence, 14 patients).
  • DECAV therapy consisted of doxorubicin 50 mg/m2 d1, dacarbazine (DTIC) 200 mg/m2/d d1-3, vindesine 2 mg/day d1-2, cisplatin 100 mg/m2 d3, and either cyclophosphamide (CPM) 200 mg/m2/d d1-3 (n = 21), or ifosfamide (IFM) 2 g/m2/d d1-3 with mesna every 4 weeks Toxicity included 18 hospital stays for cytopenia (nine patients), including 13 cases of febrile neutropenia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Blood Transfusion. Carcinosarcoma / drug therapy. Carcinosarcoma / mortality. Carcinosarcoma / secondary. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. France. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / mortality. Leiomyosarcoma / secondary. Liver Neoplasms / drug therapy. Liver Neoplasms / mortality. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / secondary. Middle Aged. Neoplasm Staging. Neutropenia. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / mortality. Sarcoma, Endometrial Stromal / secondary. Survival Analysis. Treatment Outcome. Vindesine / administration & dosage

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445254.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine; DECAV protocol
  •  go-up   go-down


14. Takeyama Y, Yamamoto M, Shima K, Nakamura T, Nakasima H, Yoshida K, Kusunose M: [A case of pulmonary carcinosarcoma with pleural effusion, progressive pleural thickening and a calcification-like lesion]. Nihon Kokyuki Gakkai Zasshi; 2009 Jul;47(7):620-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pulmonary carcinosarcoma with pleural effusion, progressive pleural thickening and a calcification-like lesion].
  • We made a diagnosis of primary adenocarcinoma of the lung.
  • Chemotherapy was performed after pleurodesis.
  • The final diagnosis was primary carcinosarcoma of the lung.
  • [MeSH-major] Carcinosarcoma / pathology. Lung Neoplasms / pathology. Pleura / pathology. Pleural Effusion, Malignant / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637805.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Tanigawa M, Kimura M, Ichioka M, Saito K, Kimura M: [A case of true pulmonary carcinosarcoma]. Nihon Kokyuki Gakkai Zasshi; 2003 Jul;41(7):496-501
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of true pulmonary carcinosarcoma].
  • The diagnosis was therefore true pulmonary carcinosarcoma.
  • The sarcoma component recurred in the remaining part of the left lung.
  • Nevertheless, chemotherapy, linac radiosurgery, percutaneous radiofrequency ablation, and partial small intestinal resection combined with rectal resection were performed.
  • Liver metastatic lesions were determined to be the adenocarcinomatous component, and the other recurrent or metastatic lesions, except for those in the brain, were all composed of poorly-differentiated sarcomatous tissue.
  • [MeSH-major] Carcinosarcoma / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12931680.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Shamseddine A, Taher A, Abou-Mourad Y, Seoud M, Khalil A: Cure of metastatic uterine carcinosarcoma to lungs: a case report. Int J Gynecol Cancer; 2003 Jan-Feb;13(1):88-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cure of metastatic uterine carcinosarcoma to lungs: a case report.
  • We present a case of uterine sarcoma with lung metastasis treated with systemic chemotherapy and with no evidence of disease for more than 5 years.
  • A 77-year-old woman underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy for carcinosarcoma of the uterus followed by external pelvic radiotherapy.
  • After four cycles of systemic chemotherapy with cisplatin and ifosfamide, the pulmonary nodules completely disappeared.
  • Currently she is still in complete remission after more than 5 years, but unfortunately she has developed myelodysplastic syndrome.
  • This is the first reported case in the literature of cured metastatic uterine carcinosarcoma to lungs, with long-term survival of 5 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / drug therapy. Carcinosarcoma / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Ifosfamide / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12631227.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


17. Murakami M, Tsukada H, Ikeda M, Watanabe M, Muramatsu T, Miyamoto T, Makino T, Yasuda S, Ide M, Nasu S: Availability of whole-body positron emission tomography (PET) for the detection of metastatic sites in recurrent uterine sarcoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):5100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Availability of whole-body positron emission tomography (PET) for the detection of metastatic sites in recurrent uterine sarcoma.
  • Accurate diagnosis of the metastatic sites is important for the treatment strategy.
  • Unfortunately current diagnostic techniques, including CT, MRI, and ultrasonography (US) are not efficient for the detection of recurrence.
  • There is little report of the experience with whole-body 18 fluorodeoxyglucose (FDG)-PET for the detection of recurrence in the follow up of patients with uterine sarcomas.
  • The purpose of this study is to evaluate the availability of FDG-PET for the detection of recurrence in patients with uterine sarcomas.
  • METHODS: Twelve patients with pathologically proven uterine sarcomas (nine leiomyosarcoma and three carcinosarcoma) took FDG-PET, CT, MRI and US for the purpose of the detection of recurrence after the primary treatment.
  • RESULTS: The final diagnoses of recurrence were established in five cases (three carcinosarcoma and two leiomyosarcoma).
  • PET scan showed all recurrent sites of intraperitoneum, liver, lung and retroperitoneal lymph nodes.
  • Positive results of PET scan did not affect the prognosis in four patients, but another patient with solitary intraperitoneal tumor by PET scan could received the chemotherapy and operation, which histologically confirmed the recurrence of leiomyosarcoma.
  • Application of PET scan for the early detection of recurrence may affect the prognosis of some patients with uterine sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015696.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Mito A, Nishino R, Akita S, Shiomi K, Daga H, Ohashi N, Arita K, Fujiwara M: [Case of pulmonary carcinosarcoma and a summary of 17 cases reported in Japan]. Nihon Kokyuki Gakkai Zasshi; 2004 Aug;42(8):749-54
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of pulmonary carcinosarcoma and a summary of 17 cases reported in Japan].
  • Despite pleurodesis and chemotherapy, he died 1.5 months after admission.
  • At autopsy, a final diagnosis of pulmonary carcinosarcoma was obtained.
  • We have summarized 17 cases of pulmonary carcinosarcoma reported in Japan.
  • [MeSH-major] Carcinosarcoma / diagnosis. Carcinosarcoma / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Fatal Outcome. Humans. Japan. Male. Pleural Effusion, Malignant / complications. Risk Factors. Smoking / adverse effects. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15455949.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down


19. Sato S, Koike T, Yamato Y, Yoshiya K, Motono N, Takeshige M, Homma K, Koizumi N, Yokoyama A, Tsukada H: A case of rapidly growing pulmonary carcinosarcoma. Int J Clin Oncol; 2010 Jun;15(3):319-24
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of rapidly growing pulmonary carcinosarcoma.
  • We report herein a case of rapidly growing pulmonary carcinosarcoma, a rare and highly malignant lung neoplasm characterized by a biphasic histopathological pattern consisting of both epithelial and sarcomatous components, and we also summarize the clinical features of this entity based on previously reported cases.
  • A 65-year-old man was referred for further examination of a lung tumor after a routine chest X-ray (CXR) showed a tumor shadow in the right upper lung zone.
  • Chest computed tomography (CT) found a 2.0 cm pulmonary mass with suspected chest wall invasion in the right upper lobe, although cytological evidence of malignancy could not be obtained despite repeated preoperative bronchoscopy.
  • The tumor grew rapidly, indicating the possibility of lung cancer.
  • The postoperative definitive diagnosis was carcinosarcoma consisting of adenocarcinoma and chondrosarcoma.
  • The patient subsequently received adjuvant chemotherapy with cisplatin and vinorelbine.
  • Consequently he underwent radiotherapy, but the disseminated tumors enlarged further while he received this treatment.
  • Findings based on previously reported cases and our case suggest that early surgical intervention and combined therapeutic strategy are the most important aspects of treatment for pulmonary carcinosarcoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinosarcoma / pathology. Chondrosarcoma / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchoscopy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease Progression. Humans. Male. Neoplasm Staging. Pleural Neoplasms / radiotherapy. Pleural Neoplasms / secondary. Pneumonectomy. Tomography, X-Ray Computed. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Mol Pathol. 2008 Sep;17(3):151-8 [18382357.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1514-26 [10584705.001]
  • [Cites] Am J Surg Pathol. 1996 Mar;20(3):277-85 [8772780.001]
  • [Cites] Semin Diagn Pathol. 1993 May;10(2):118-27 [8367621.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5B):3893-7 [17094419.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Apr;23(4):461-6 [12694760.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):510-6 [11914631.001]
  • [Cites] Am J Clin Pathol. 1982 Feb;77(2):123-36 [7064914.001]
  • [Cites] AJR Am J Roentgenol. 1997 Sep;169(3):691-4 [9275879.001]
  • [Cites] Eur J Cardiothorac Surg. 1996;10(6):403-7 [8817133.001]
  • [Cites] Ann Thorac Surg. 2007 Sep;84(3):973-80 [17720411.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Sep;134(3):619-23 [17723808.001]
  • [Cites] Br J Dis Chest. 1985 Jan;79(1):83-94 [3986115.001]
  • [Cites] Mayo Clin Proc. 1984 Sep;59(9):598-603 [6381913.001]
  • (PMID = 20217450.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


20. Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G, Lentz SS, Sorosky J, Hsiu JG: A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol; 2000 Nov;79(2):147-53
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.
  • OBJECTIVE: The aims of this study were to substantiate the previously reported activity of ifosfamide in patients with advanced, persistent, or recurrent carcinosarcoma (mixed mesodermal sarcoma) of the uterus, and to determine whether the addition of cisplatin results in an improved response or survival.
  • METHODS: Patients were randomized to receive ifosfamide (1.5 g/m(2)/day) times 5 days every 3 weeks for eight courses with mesna uroprotection, with or without cisplatin (20 mg/m(2)/day) times 5 days.
  • No patient had received previous chemotherapy.
  • Percentages of adverse effects reported in 191 patients receiving chemotherapy included (ifosfamide/cisplatin-ifosfamide) grade 3 or 4 granulocytopenia (36/60), grade 3 or 4 anemia (8/17), grade 3 or 4 central nervous system toxicity (19/14), and grade 3 or 4 peripheral neuropathy (1/12).
  • Treatment may have contributed to the deaths of 6 patients treated with full doses of ifosfamide and cisplatin for 5 days.
  • The proportion of patients responding to ifosfamide alone versus ifosfamide-cisplatin therapy was (0.36 versus 0.54) overall, 0.47 versus 0.61 for pelvic, 0.21 versus 0.54 for lung, and 0.33 versus 0.40 for "other" metastatic sites of measurable disease.
  • CONCLUSION: The addition of cisplatin to ifosfamide appears to offer a small improvement in progression-free survival over ifosfamide alone in the management of advanced carcinosarcoma of the uterus; the added toxicity may not justify the use of this combination.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / drug therapy. Ifosfamide / therapeutic use. Uterine Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • [CommentIn] Gynecol Oncol. 2000 Nov;79(2):145-6 [11063635.001]
  • (PMID = 11063636.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


21. Möbus VJ, Gerharz CD, Weikel W, Merk O, Dreher L, Kreienberg R, Moll R: Characterization of a human carcinosarcoma cell line of the ovary established after in vivo change of histologic differentiation. Gynecol Oncol; 2001 Dec;83(3):523-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of a human carcinosarcoma cell line of the ovary established after in vivo change of histologic differentiation.
  • We describe the establishment of a carcinosarcoma cell line of the ovary after in vivo selection.
  • At the time of establishment, the patient underwent secondary debulking and was pretreated with six cycles of cis-platinum/epirubicin/cyclophosphamide.
  • RESULTS: The first histologic report of the patient described a papillary cystadenocarcinoma, which changed to a carcinosarcoma with predominantly sarcomatous differentiation at secondary debulking.
  • This cell line is aneuploid and shows no expression of the tumor-associated antigens CA-125 and CEA, but an overexpression of MDR-1, lung resistance protein, p53, and topoisomerase I and II, but not of multidrug-resistance-associated protein.
  • The histologic and immunocytochemical comparison of the primary and the relapsed tumor proved evidence of an in vivo change of differentiation from predominantly papillary cystadenocarcinoma to carcinosarcoma.
  • CONCLUSION: The change of histologic differentiation was apparently due to a selection process caused by platinum-containing chemotherapy.
  • [MeSH-major] Carcinosarcoma / pathology. Ovarian Neoplasms / pathology. Tumor Cells, Cultured


22. Gadducci A, Cosio S, Romanini A, Genazzani AR: The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol; 2008 Feb;65(2):129-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total abdominal hysterectomy and bilateral salpingo-oophorectomy represents the standard surgical treatment.
  • Pelvic and/or para-aortic lymphadenectomy is indicated for carcinosarcoma, but not for leiomyosarcoma and undifferentiated endometrial sarcoma.
  • Carcinosarcoma also requires a comprehensive surgical peritoneal staging.
  • Postoperative treatment of uterine sarcomas has been long debated.
  • There is little evidence in the literature supporting the use of adjuvant chemotherapy in any gynaecological sarcomas except for carcinosarcomas.
  • However, uterine sarcomas have a high tendency to develop distant recurrences, and recent data on adjuvant chemotherapy in soft tissue sarcomas are promising.
  • As for the drugs to be used, it is worth noting that in a Swiss study, the combination of ifosfamide (IFO) and doxorubicin (DOX) obtained similar response rates in advanced gynaecological sarcomas and in advanced soft tissue sarcomas of other sites.
  • In our decision-making scheme for early-stage disease, patients with leiomyosarcoma or undifferentiated endometrial sarcoma should receive adjuvant doxorubicin/epidoxorubicin (EPIDX)+ifosfamide, and those with carcinosarcoma should be treated with adjuvant cisplatin (CDDP)-based chemotherapy.
  • The same drug regimens are used for the treatment of advanced disease.
  • Sequential pelvic radiotherapy following chemotherapy could be delivered to selected cases.
  • Recurrent disease often requires the integration of different therapeutic modalities, but no curative option is currently available with the possible exception of surgery for lung metastases and hormone therapy with or without debulking surgery for recurrent low-grade endometrial stromal sarcoma.
  • Patients should be encouraged to enter clinical trials designed to identify new active drugs for these malignancies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Neoadjuvant Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706430.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 177
  •  go-up   go-down


23. Nogusa H, Yamamoto K, Yano T, Kajiki M, Hamana H, Okuno S: Distribution characteristics of carboxymethylpullulan-peptide-doxorubicin conjugates in tumor-bearing rats: different sequence of peptide spacers and doxorubicin contents. Biol Pharm Bull; 2000 May;23(5):621-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasma and tissue distribution of conjugates of carboxymethylpullulan (CMPul) and doxorubicin (DXR), either bound directly or through three types of tetrapeptide spacers, was studied after intravenous injection to rats bearing Walker 256 carcinosarcoma and compared with that of DXR.
  • Disposition characteristics of [3H]CMPul in rats bearing Walker 256 carcinosarcoma indicate that pullulan, which had molecular weight over 50 kDa, is a suitable macromolecular carrier for tumor targeting in cancer chemotherapy by carboxymethylation.
  • CMPul-DXR conjugates were also distributed in the reticuloendothelial organs, such as liver, spleen and bone marrow; however, the tissue concentrations of the conjugates in the heart, lung and muscle were lower than those of DXR.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Carcinosarcoma / metabolism. Doxorubicin / pharmacokinetics. Glucans / pharmacokinetics
  • [MeSH-minor] Animals. Carbohydrate Sequence. Female. Male. Mice. Molecular Sequence Data. Peptides / administration & dosage. Peptides / chemistry. Rats. Rats, Wistar. Tissue Distribution. Tritium

  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10823676.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucans; 0 / Peptides; 0 / carboxymethylpullulan; 10028-17-8 / Tritium; 80168379AG / Doxorubicin
  •  go-up   go-down


24. García Mediero JM, Alonso Dorrego JM, Nuñez Mora C, Pastor Arquero T, De Fata FR, Cisneros Ledo J, Perez Mies B, Picazo García ML, de la Peña Barthel YJ: [Early-onset sarcomatoid renal carcinoma. Report of a new case and comparison of the same case with another appearing at a mature age]. Arch Esp Urol; 2002 Sep;55(7):843-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also review etiological, diagnostic and therapeutic features.
  • RESULTS: Despite aggressive surgery and adjuvant chemotherapy it has a very poor prognosis, with disease progression within 6 months in both cases.
  • CONCLUSIONS: Sarcomatoid renal cell carcinoma is an infrequent entity, extremely aggressive and requires radical surgery at the time of diagnosis due to its advanced stage, although results are poor.
  • [MeSH-major] Carcinosarcoma / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Age of Onset. Aged. Antineoplastic Agents, Phytogenic / therapeutic use. Chemotherapy, Adjuvant. Disease Progression. Fatal Outcome. Female. Hepatectomy / methods. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymph Node Excision. Nephrectomy. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12380314.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


25. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW: Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol; 2008 Jan 20;26(3):361-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Common treatment-related adverse events included reversible mouth sores and rash.
  • Four patients (one each with non-small-cell lung cancer, mixed müllerian tumor [carcinosarcoma], renal cell carcinoma, and Ewing sarcoma) experienced confirmed partial responses, and three additional patients had minor tumor regressions.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Neoplasms / drug therapy. Protein Kinases / metabolism. Sirolimus / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Area Under Curve. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Prognosis. Survival Rate. TOR Serine-Threonine Kinases


26. Hirano H, Yoshida T, Sakamoto T, Yoshimura H, Fukuoka M, Tachibana S, Saito H, Ohkubo E, Nakasho K, Nishigami T: Pulmonary pleomorphic carcinoma producing hCG. Pathol Int; 2007 Oct;57(10):698-702
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A diagnosis of PC was made due to hCG expression in approximately 20% of the spindle and polygonal cells on immunohistology.
  • The patient died due to metastases 1 year after the operation, even though the patient had been at stage 1B at the time of the operation and appropriate chemotherapy had been given.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinosarcoma / metabolism. Chorionic Gonadotropin / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Aged, 80 and over. Combined Modality Therapy. Fatal Outcome. Female. Humans. Radiography, Thoracic. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17803660.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin
  •  go-up   go-down


27. Froehner M, Gaertner HJ, Manseck A, Wirth MP: Durable complete remission of metastatic sarcomatoid carcinoma of the bladder with cisplatin and gemcitabine in an 80-year-old man. Urology; 2001 Nov;58(5):799
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sarcomatoid carcinoma arising in the bladder is a rare and notoriously aggressive variant of urothelial carcinoma for which an effective systemic treatment has not been reported up to now.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / drug therapy. Deoxycytidine / analogs & derivatives. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Cisplatin / administration & dosage. Humans. Lung Neoplasms / secondary. Male. Remission Induction

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11711370.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Kijima Y, Umekita Y, Yoshinaka H, Owaki T, Sakamoto A, Yoshida H, Aikou T: A case of breast carcinoma with cartilaginous and osseous metaplasia. Breast Cancer; 2006;13(2):214-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five months after the operation, she developed lung metastases.
  • Although she received systemic chemotherapy, the lesions increased in number and grew rapidly.
  • [MeSH-major] Bone Neoplasms / secondary. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Carcinosarcoma / secondary. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Biopsy, Needle. Diagnosis, Differential. Disease Progression. Fatal Outcome. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Mammography. Mastectomy, Segmental. Metaplasia. Middle Aged. Risk Assessment


29. Murakami M, Tsukada H, Shida M, Watanabe M, Maeda H, Koido S, Hirasawa T, Muramatsu T, Miyamoto T, Nasu S, Yasuda S, Kajiwara H, Yasuda M, Ide M: Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):854-60
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas.
  • We evaluated the usefulness of whole-body positron emission tomography (PET) using F-18 fluorodeoxyglucose (FDG-PET) for the detection of recurrence in follow-up patients after primary treatment of uterine sarcoma.
  • Eight patients with pathologically proven uterine sarcoma underwent FDG-PET, computed tomography (CT), and ultrasonography (US).
  • PET revealed recurrent sites in the intraperitoneum, liver, lung, bone, and retroperitoneal lymph nodes.
  • Positive PET findings did not affect the prognosis in three of the five recurrent patients; however, the remaining two patients consequently underwent the combination therapy consisting of surgery and chemotherapy and survived for more than 1 year after the positive FDG-PET results.
  • Application of PET imaging for the early detection of recurrent sites was useful for the decision of treatment strategy for patients with recurrent uterine sarcoma.
  • [MeSH-major] Carcinosarcoma / radionuclide imaging. Fluorodeoxyglucose F18. Leiomyosarcoma / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed. Uterine Neoplasms / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681773.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


30. Boroumand N, Raja V, Jones DV, Haque AK: SYT-SSX2 variant of primary pulmonary synovial sarcoma with focal expression of CD117 (c-Kit) protein and a poor clinical outcome. Arch Pathol Lab Med; 2003 Apr;127(4):e201-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous reports have suggested that the soft tissue synovial sarcomas with SYT-SSX2 phenotype have a favorable clinical outcome.
  • After the patient underwent chemotherapy and brachytherapy, the specimen from a left pneumonectomy showed a large spindle cell tumor, which was reclassified as a synovial sarcoma based on the results of immunophenotyping and molecular genetic studies.
  • Differentiation between sarcoma and carcinosarcoma is crucial for implementing appropriate therapy.
  • Furthermore, if the tumor expresses c-Kit, it may respond to target-based therapy.
  • [MeSH-major] Genetic Variation / genetics. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Proteins c-kit / biosynthesis. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / genetics

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12683902.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down






Advertisement